Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition of letrozole resistance in cell clones generated from MCF-7/AROM-1 aromatase-expressing bre...
Príomhchruthaitheoirí: | Cavazzoni, A, Bonelli, M, Fumarola, C, La Monica, S, Airoud, K, Bertoni, R, Alfieri, R, Galetti, M, Tramonti, S, Galvani, E, Harris, A, Martin, L, Andreis, D, Bottini, A, Generali, D, Petronini, P |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
2012
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
de réir: Cavazzoni, A, et al.
Foilsithe / Cruthaithe: (2012) -
Synergistic activity of letrozole and sorafenib on breast cancer cells.
de réir: Bonelli, M, et al.
Foilsithe / Cruthaithe: (2010) -
DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
de réir: Foroni, C, et al.
Foilsithe / Cruthaithe: (2009) -
The identification of the mTOR-regulated phosphoproteome and a mediator of feedback inhibition to P13K-Akt
de réir: Hsu, Peggy Ping
Foilsithe / Cruthaithe: (2011) -
Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
de réir: Grozinsky-Glasberg, S, et al.
Foilsithe / Cruthaithe: (2008)